Marinus Pharmaceuticals’ (MRNS) “Sector Perform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reaffirmed their sector perform rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Monday morning, Marketbeat.com reports. The brokerage currently has a $3.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $24.00.

Several other analysts have also commented on the stock. Cantor Fitzgerald reissued an overweight rating and set a $28.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. StockNews.com lowered shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, March 6th. Oppenheimer reissued a market perform rating and set a $9.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Finally, HC Wainwright reissued a buy rating and set a $27.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and an average price target of $16.07.

Marinus Pharmaceuticals Trading Down 2.1 %

Shares of NASDAQ:MRNS opened at $1.41 on Monday. The company has a 50 day moving average of $8.55 and a 200-day moving average of $8.40. The firm has a market cap of $77.45 million, a P/E ratio of -0.54 and a beta of 0.91. Marinus Pharmaceuticals has a twelve month low of $1.11 and a twelve month high of $11.26. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The company had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. During the same period in the prior year, the company posted ($0.76) earnings per share. As a group, analysts anticipate that Marinus Pharmaceuticals will post -2.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MRNS. MetLife Investment Management LLC increased its stake in Marinus Pharmaceuticals by 63.8% in the 1st quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 7,928 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Marinus Pharmaceuticals by 2.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock valued at $889,000 after buying an additional 2,281 shares during the period. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals in the 1st quarter valued at approximately $317,000. Goldman Sachs Group Inc. increased its stake in Marinus Pharmaceuticals by 3.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 156,949 shares of the biopharmaceutical company’s stock valued at $1,468,000 after buying an additional 5,380 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Marinus Pharmaceuticals in the 1st quarter valued at approximately $40,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.